Kenvue

KVUE

Market cap $33.4B

The use of Tylenol by women during pregnancy was not associated with autism in their children, according to results of a nationwide ​study in Denmark published on Monday.

Consumer staples lagged in 2025 and into this year, creating rare entry points for long-term income investors. Dividend durability remains strong in these four tickers despite short-term earnings pressure across major brands.

Kenvue (KVUE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Medtronic and Kimberly-Clark are Dividend Aristocrats trading well below historical valuations, offering compelling buy-the-dip opportunities. MDT has strong revenue growth, a robust innovation pipeline, and a 3.3% yield, with a forward P/E of 15.4 versus its historical 17.5. KMB is executing on transformation and innovation, with margin gains, a 5.2% yield, and a forward P/E of 13.0, far below its historical 17.7.

Tylenol use among pregnant women fell after U.S. President Donald Trump linked autism to the over-the-counter pain relief medicine, according to an analysis of U.S. emergency room prescribing patterns published in the UK medical journal Lancet.

Investors looking for stocks in the Consumer Products - Staples sector might want to consider either Kenvue (KVUE) or Procter & Gamble (PG). But which of these two stocks offers value investors a better bang for their buck right now?

The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY and 39 posting double-digit gains this year already. Dividend growth is lagging, with 2026's average increase currently at 3.22%, below last year's trend and potentially signaling headwinds.

A Texas judge on Thursday rejected Kenvue's bid to dismiss a lawsuit by that state's Attorney General Ken Paxton accusing the company of concealing autism and other risks to children when pregnant women use Tylenol.

After a 35-year career in the finance industry, including two decades as an institutional stockbroker at Bear Stearns, Lehman Brothers, and Morgan Stanley, I developed an institutional perspective on dividend-focused investing.

On Feb. 18, 2026, investors weighed Kenvue's earnings momentum against looming merger costs and related risks.